Conflit d’intérêt à l’#OMS : l’Europe appuie de toute sa force la nomination comme membre au groupe de travail sur le financement de la recherche d’un cadre de #Novartis ... qui a préparé plusieurs projets pour ce groupe.
European members of #WHO Executive Board take hard line on nomination of Novartis official to R&D group | Knowledge Ecology International
►http://keionline.org/node/1060
At the 128th meeting of the WHO Executive Board (EB), the European members of the board are reportedly taking a hard line on the proposal by Switzerland to have Paul Herrling, an executive of Novartis, appointed to the WHO Consultative Expert Working Group (CEWG) on R&D financing. Our earlier blogs on this controversy are available here and here).
Even some industry observers are surprised that Herrling’s name was put forward for the body, given his leading role in the FRIND and PDP Plus funding proposals that will be considered by the CEWG.